Opdualag — The FDA approved Bristol Myers Squibb’s Opdualag immunotherapy — a fixed-dose combination of nivolumab and relatimab — for the treatment of unresectable or metastatic melanoma March 18.
Ztalmy — Ganaxolone, which goes by the brand name Ztalmy, was approved March 18 to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients ages 2 and older.
Generic Symbicort — On March 15, the FDA approved the first generic version of Symbicort inhalation aerosol to treat asthma and chronic obstructive pulmonary disease. The generic drug-device combination product is a metered-dose inhaler containing budesonide and formoterol.
Vonjo — Federal regulators approved pacritinib, which goes by the brand name Vonjo,Feb. 28 for the treatment of intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets.
Pyrukynd —Mitapivat, which goes by the brand name Pyrukynd, was approved Feb. 17 to treat hemolytic anemia in adults with pyruvate kinase deficiency.
Enjaymo — The FDA approved sutimlimab-jome, which goes by the brand name Enjaymo, Feb. 2 to decrease the need for red blood cell transfusion from hemolysis for adults with cold agglutinin disease.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
